Broadfin Capital

Kevin Kotler, the founder, served as the sole portfolio manager and made all final investment decisions. He built the firm after working as a healthcare analyst and maintained a flat structure without co-portfolio managers, which kept decision-making concentrated and fast.

Broadfin ran a concentrated, long-biased healthcare equity strategy focused on biotechnology, specialty pharmaceuticals, and medical devices. The firm targeted event-driven catalysts — FDA decisions, clinical-trial results, M&A — and typically held fewer than 25 positions, betting heavily on single names rather than diversifying across the sector.

The flagship strategy appears to have been wound down. In September 2019, SEC filings showed Broadfin had liquidated nearly all public-equity positions, leaving a single remaining holding. Reuters reported the wind-down at the time (per Reuters, September 2019). No subsequent 13F filings suggest a relaunch.

Auspex Pharmaceuticals was Broadfin's signature win. The firm built an 8.4% stake at an average cost around $15 per share and realized over $150 million when Teva Pharmaceutical Industries acquired Auspex for $101 per share in cash in 2015, a return exceeding 10x.

Broadfin occasionally took an activist posture. The firm filed 13D forms on select holdings, indicating intent to influence management or strategic direction, but it was predominantly known as a high-conviction fundamental investor rather than a dedicated activist. Its position sizing alone often gave it boardroom influence without public campaigns.